Company profile for MEI Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a San Diego-based, late-stage pharmaceutical company focused on building a leading oncology franchise. Our portfolio of drug candidates contains four clinical-stage candidates, including one candidate in an ongoing global registration trial (pracinostat), and another candidate (ME-401) that is entering a Phase 2 clinical trial which we intend to submit to the U.S. Food and Drug administration to support an accelerated a...
We are a San Diego-based, late-stage pharmaceutical company focused on building a leading oncology franchise. Our portfolio of drug candidates contains four clinical-stage candidates, including one candidate in an ongoing global registration trial (pracinostat), and another candidate (ME-401) that is entering a Phase 2 clinical trial which we intend to submit to the U.S. Food and Drug administration to support an accelerated approval marketing application. Our drug candidates target different mechanisms critical to overcoming cancer progression and drug resistance:

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
3611 Valley Centre Drive, Suite 500 San Diego, CA 92130
Telephone
Telephone
(858) 369-7100
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20250910086737/en/MEI-Pharma-Inc.-Rebrands-as-Lite-Strategy-Inc.-Adopts-New-NASDAQ-Ticker-LITS

BUSINESSWIRE
10 Sep 2025

https://www.fiercebiotech.com/biotech/mei-pharma-leaves-biotech-woes-behind-rebrand-crypto-company

FIERCE BIOTECH
10 Sep 2025

https://www.businesswire.com/news/home/20250805082856/en/MEI-Pharma-Acquires-Litecoin-Launches-%24100M-Institutional-Treasury-Strategy-with-Charlie-Lee-and-GSR-Advising

BUSINESSWIRE
05 Aug 2025

https://www.businesswire.com/news/home/20250722937784/en/MEI-Pharma-Announces-Closing-of-%24100000000-Private-Placement-to-Initiate-Litecoin-Treasury-Strategy-Becoming-First-and-Only-Publicly-Traded-LTC-Holder-on-a-National-Exchange

BUSINESSWIRE
22 Jul 2025

https://www.businesswire.com/news/home/20250718252887/en/MEI-Pharma-Announces-%24100000000-Private-Placement-to-Initiate-Litecoin-Treasury-Strategy-Becoming-First-and-Only-Publicly-Traded-LTC-Holder-on-a-National-Exchange

BUSINESSWIRE
18 Jul 2025

https://www.businesswire.com/news/home/20250513634282/en/MEI-Pharma-Reports-Third-Quarter-Fiscal-Year-2025-Cash-Position

BUSINESSWIRE
13 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty